Canagliflozin may not be good for the heart, FDA says

January 10, 2013

Canagliflozin (Janssen Research & Development), developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, raised the level of bad cholesterol in patients during clinical trials and may post heart risks, according to FDA and reported by Reuters.


Related Content:

Clinical Pharmacology | News